PharmaVOICE - 
February 2020
Purchase Issue
In Every Issue
Letter from the Editor
What’s old is new again This month’s cover story addresses [...]
By

Taren Grom, Editor

Upfront
Mylan’s Team in Turkey is Helping Women and Children More [...]
By

PharmaVOICE Staff

HealthTech
Newly FDA-Approved Ingestible Pill Challenges Struggling Proteus Trend Watch: From [...]
By

PharmaVOICE Staff

Artificial Intelligence
AI Tech Company Partners with Roche for Clinical Trial Work [...]
By

PharmaVOICE Staff

Innovator’s Corner
A Potential Cure for Hepatitis B Dr. Lawrence Blatt, CEO, [...]
By

https://www.pharmavoice.com/?p=463212

Last Word
Preventing a Bad Moment from Turning Into a Bad Day [...]
By

Michael O’Brien, executive business coach and author

On The Cover

New Pipeline Pathways
The industry is becoming more strategic about repurposing its existing and shelved drugs. In the 1960s it became apparent that the drug thalidomide caused horrible birth defects in babies when pregnant mothers took it to treat their nausea. It was removed from the market. However today, that same drug is being used to treat a [...]
By

Robin Robinson

Features

SHOWCASE: Rare Disease: Rare But Not Scarce: The Struggle Faced By Millions
A single rare disease may afflict just a small number of people, but collectively up to 400 million people globally live with a rare disease. Exactly what is a rare disease? Collectively, rare isn’t scarce or infrequent. That’s the message that the organizers of Rare Disease Day 2020 are striving to promote. Worldwide, there are [...]
By

PharmaVOICE Staff

Lessons Learned from rare Disease First Commercial Launches
There’s nothing more exciting, and more nerve-wracking, than a new product launch — even more so when it’s a company’s first commercial launch. We’ve had the privilege of working on more than 10 first commercial launches, most of them in rare disease. As an agency partner we’ve worked with biotechs as they’ve evolved from R&D [...]
By

Annemarie Armstrong, Executive VP, Director of Client Services, Dudnyk

How the “Power of Why” Can Improve Adherence Rates in Rare Disease
Best-selling author and motivational speaker, Simon Sinek, is best known for his 2009 Ted Talk challenging organizations to set aside their list of product benefits and features to focus on the core purpose of their existence. He asks, WHY are you motivated to do what you do every day? Sinek suggests that organizations that can [...]
By

Kathi Hensen, Chief Operating Officer, Patient Services and Chief Patient Officer, EVERSANA

Finding Patients With Rare Diseases — Two Truths and a Lie
The hope for many companies developing drugs for rare diseases is this: the significant unmet need, given a dearth of treatment options, will drive demand and thus product uptake. Unfortunately, the reality is more challenging. While we have seen a significant increase in the number of drugs for rare diseases, accurate diagnosis rates of rare [...]
By

Susan Abedi, Executive VP, Commercial Solutions, 81qd

Agile Marketing
Agile allows agencies to move twice as fast with more favorable outcomes. Agency marketers are very accustomed to putting out fires, juggling tasks, as well as hats, and wading their way through daily chaos as they attempt to create successful campaigns for clients. According to our experts, there is a way to calm waters: agile [...]
By

Robin Robinson

SHOWCASE: Outsourcing in a New Decade: Changing the Relationship
To stay competitive, companies have increasingly needed to outsource a range of activities — from clinical trials to commercialization. The past decade has been one of rapid change for the pharmaceutical industry. It’s gone through multiple large and small mergers and acquisitions, it has experienced a rapid rise in -omics and other science innovations along [...]
By

PharmaVOICE Staff

Critical Considerations for Outsourcing Medical Writing
As the landscape for drug development and regulatory approval continues to become more complex, the need for experts who can transform large quantities of clinical trial data into accurate, understandable and compliant documents has never been greater. Medical writers who understand the drug development and regulatory strategy, and who are experienced in developing the documents [...]
By

Brian Smith, Director, Scientific Writing, Cardinal Health Regulatory Sciences

The New Roaring 20s: How Outsourced Commercialization is the Revolution We Need
The Great Gatsby Era was an exciting time of new prosperity, infinite creativity, and dramatic social change. Long-standing social norms and traditions gave way to the “mass culture” and consumerism that modernized American society. “What will they think of next?” was a popular expression that defined the era. On the 100-year anniversary of this revolutionary [...]
By

Greg Skalicky, Chief Revenue Officer, EVERSANA

R&D INFLUENCERS
Influencers have the power to positively change the status quo because of their authority, knowledge, position, or relationship with their audience. The United States is the largest market for biopharmaceuticals, accounting for about one-third of the global market, and is the world leader in biopharmaceutical R&D. According to PhRMA, U.S. firms conduct more than half [...]
By

PharmaVOICE Staff

R&D INFLUENCER: Dr. Joanne Santomauro — Ancillere LP
Tackling Ancillary Supply Challenges with Innovative Solutions When a pharmaceutical client came to Joanne Santomauro nearly 15 years ago with a request to help with a complex and expensive ancillary supply challenge, she didn’t hesitate. She launched Ancillare and began the journey to create and revolutionize ancillary supply chain management for the clinical research industry. [...]
By

Dr. Joanne Santomauro, CEO, Ancillare LP

R&D INFLUENCER: Bert Hartog, Ph.D. — Janssen Pharmaceutical Companies of Johnson & Johnson
Unlocking clinical Bottlenecks We need to make more trials more accessible to more people. participate Bert Hartog, Ph.D., senior director at Janssen Clinical Innovation, Janssen Research & Development LLC is driven to eliminate the challenges preventing patients from participating in clinical trials. “The number of people who know about trials is in the 5% to [...]
By

Bert Hartog, Ph.D., Senior Director, Janssen Clinical Innovation, Janssen Pharmaceutical Companies of Johnson & Johnson

R&D INFLUENCER: Jill Johnston — WCG, Clinical Services Organization
Breaking Down the Roadblocks to Site Activation My focus is on getting life-saving drugs to patients as quickly as possible by reducing the time it takes sites to enroll patients into trials. There’s a big difference between people with a vision and those who can execute on that idea. Jill Johnston, president of WCG’s study [...]
By

Jill Johnston, President, Study Planning and Site Optimization Division, WCG, Clinical Services Organization

Oncology Market Insights
Analysts and experts discuss scientific, technological, and access advancements in the oncology area. Oncology clinical development activities are being undertaken by more than 700 companies and are at record high levels, according a report by the IQVIA Institute for Human Data Science. But despite some improvement in oncology trial productivity and the prospect of further [...]
By

Denise Myshko

Commanders & Chiefs: Innovators
Chief innovators provide their insights on what innovation means to them, keys to driving innovation, and what it takes to foster an innovation-driven company culture. Defining Innovation Garde. We define innovation as breaking business barriers through measurable and unique client-focused solutions. These solutions are by no means static; they are dynamic and shift with time, [...]
By

PharmaVOICE Staff

FEEDBACK